Genelux Corporation (GNLX)
NASDAQ: GNLX · Real-Time Price · USD
2.450
-0.020 (-0.81%)
At close: Sep 29, 2026, 4:00 PM EDT
2.460
+0.010 (0.41%)
After-hours: Sep 29, 2026, 7:30 PM EDT
Genelux Revenue
Genelux had revenue of $8.00K in the twelve months ending June 30, 2026. In the year 2025, Genelux had annual revenue of $8.00K.
Revenue (ttm)
$8.00K
Revenue Growth
n/a
P/S Ratio
13,723.68
Revenue / Employee
$308
Employees
26
Market Cap
109.79M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.00K | - | - |
| Dec 31, 2024 | 8.00K | -162.00K | -95.29% |
| Dec 31, 2023 | 170.00K | -10.90M | -98.46% |
| Dec 31, 2022 | 11.07M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Seer, Inc. | 14.22M |
| Rani Therapeutics Holdings | 4.88M |
| Equillium | 4.39M |
| Cibus | 4.35M |
| Milestone Pharmaceuticals | 2.34M |
GNLX News
- 13 days ago - Genelux assumed with a Buy at Lucid Capital - TheFly
- 20 days ago - Genelux publishes case report from dose escalation portion of OLVI-VEC-202-SCLC - TheFly
- 20 days ago - Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy - GlobeNewsWire
- 6 weeks ago - Genelux reports Q2 EPS (21c), consensus (20c) - TheFly
- 6 weeks ago - Genelux expects cash to fund operations into Q1 of 2027 - TheFly
- 6 weeks ago - Genelux reports Q2 EPS (21c), consensus (20c) - TheFly
- 6 weeks ago - Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - GlobeNewsWire
- 6 weeks ago - Genelux Quarterly report: Q2 2026 - Filings